IIA – Primary Care Prescribing Plan 2021 – 2022
Primary Care Prescribing Plan 2021 – 2022
A range of prescribing activities and projects are described, aimed at improving the quality of pharmaceutical care and cost effective use of medicines in Primary Care.
No public involvement planned.
20/05/2021
| Name | Job Title | Date of IIA training |
|---|---|---|
| Chris Miller
(Facilitator, Report Writer) |
Primary Care and Community Pharmacy Coordinator, NHS Lothian | August 2016 |
| Mike Massaro-Mallinson | EHSCP Locality Manager | |
| Gillian Brunton | Advanced Clinical Pharmacist, EHSCP | |
| Karen Reid | Advanced Clinical Pharmacist, EHSCP | |
| Mark Hunter | Head of PCCO Finance, NHS Lothian | |
| Douglas McGown | General Practitioner, WLHSCP | |
| Dervilla Bray | Prescribing Advisor, ELHSCP | |
| June Edwards | Advanced Clinical Pharmacist, EHSCP | |
| Wendy Carswell | Advanced Clinical Pharmacist, EHSCP | |
| Ross McLeod | Assistant Management Accountant, NHS Lothian | |
| Neil Ferguson | General Manager, WLHSCP | |
| Katie Johnston | Advanced Clinical Pharmacist, EHSCP | |
| Alan Millarvie | Advanced Clinical Pharmacist, ELHSCP | |
| Carol Holmes | Lead Pharmacist, WLHSCP |
| Evidence | Available – detail source | Comments: what does the evidence tell you with regard to different groups who may be affected / and to the environmental impacts of your proposal |
|---|---|---|
| Data on populations in need | Our Health, Our Care, Our Future. 2014. | Outline of NHS Lothian demographics, inequalities and ill health data.
No adverse impact on population identified from plan. |
| Data on service uptake/access | Our Health, Our Care, Our Future. 2014.
Prescribing Data |
Outline of NHS Lothian demographics, inequalities and ill health data.
Primary Care prescribing: drug names, volume, cost prescribed each month. No adverse impact on population identified from plan. |
| Data on socio-economic disadvantage e.g. low income, low wealth, material deprivation, area deprivation. | Our Health, Our Care, Our Future. 2014. | Outline of NHS Lothian demographics, inequalities and ill health data.
No adverse impact on population identified from plan. |
| Data on equality outcomes | None | Data on equality outcomes in relation to prescribing not identified, however no adverse impact on population identified from plan. |
| Research/literature evidence | Clinical Guidance
Lothian Joint Formulary Prescribing Data |
All interventions and projects follow clinical guidance and aim to improve quality of prescribing as well as cost effectiveness. |
| Public/patient/client experience information | None | Any changes made to treatment will be done in partnership with the patient and followed up post change. No adverse impact on population identified from plan. |
| Evidence of inclusive engagement of people who use the service and involvement findings | None | Service users were not consulted during IIS, however no adverse impact on population identified from plan. |
| Evidence of unmet need | None | Evidence of unmet need in relation to prescribing not identified, however no adverse impact on population identified from plan. |
| Good practice guidelines | National Guidance (NICE/SIGN etc)
Lothian Joint Formulary |
Clinical guidance exists to cover all aspects of the Prescribing Efficiency plan within each individual process. No adverse impact identified from plan. |
| Carbon emissions generated/reduced data | None | No evidence of data on carbon emissions in relation to prescribing identified, however no adverse impact identified from plan and potential positive benefits. |
| Environmental data | None | No evidence of data on environmental impact in relation to prescribing identified, however no adverse impact identified from plan and potential positive benefits. |
| Risk from cumulative impacts | None | No evidence identified of risk of cumulative impacts from prescribing, however no adverse impact on population identified from plan. |
| Other (please specify) | ||
| Additional evidence required |
| Equality, Health and Wellbeing and Human Rights | Affected populations |
|---|---|
| Positive
Positive impacts identified through quality improvement projects, such as medication review, polypharmacy review and a range of projects based on national clinical guidance. Projects have been developed through existing clinical governance structures, involving specialist input when required. Negative No negative impacts identified on patients with protected characteristics. All projects rely on patient consent and treatment changes can be reversed if required. Potential difficulties in communicating with patients were identified. Training and support exists in NHS Lothian to help patients with communication difficulties and steps will be taken to ensure these resources are available to teams. Potential impact identified on staff implementing the plan through balancing with current workload. Steps will be taken to balance workload and ensure the plan is built into job descriptions and work plans. |
Potentially all population groups may be affected by the plan as Primary Care prescribing covers the full population of NHS Lothian.
Staff working with the plan. |
| Environment and Sustainability including climate change emissions and impacts | Affected populations / areas |
|---|---|
| Positive
Several projects aim to reduce medicines waste which will have a positive environmental impact. Projects involving inhaler use expected to support reduction in greenhouse gas emissions. Negative No adverse impact identified. |
Potentially all population groups and areas may be affected by the plan. |
| Economic including socio-economic disadvantage | Affected populations / areas |
|---|---|
| Positive
Positive impacts identified though cost effective use of medicines. Projects aim to improve quality of prescribing outcomes to support service quality and access. Negative No adverse impact identified. |
Potentially all population groups and areas may be affected by the plan. |
GP independents contractors, working in line with NHS Lothian guidance on prescribing, and NHS Lothian values including the rights of all protected populations.
Any changes to treatment will be communicated by the prescriber or member of the practice team, taking into account all individual needs. Changes to treatment will be reviewed and can be altered is necessary.
Strategic Environmental Assessment
Positive impact expected from reduced medicines waste, potential reduced gases from MDI inhalers – not possible to quantify.
If further evidence is required, please note how it will be gathered. If appropriate, mark this report as interim and submit updated final report once further evidence has been gathered.
| Specific actions (as a result of the IIA which may include financial implications, mitigating actions and risks of cumulative impacts) | Who will take them forward (name and job title | Deadline for progressing | Review date |
|---|---|---|---|
| Research additional communication support tools and circulate | Chris Miller | August 2021 | |
| Balance staff workplans and workload expectations to include actions from this plan | Pharmacotherapy Implementation Group | August 2021 |
No
Any changes to prescribing will be monitored locally by the prescribing team and any impacts will be assessed as they arise.
Name
Chris Miller
Date
25/05/2021
Completed and signed IIAs should be sent to:
impactassessments@nhslothian.scot.nhs.uk to be published on the NHS website https://www.nhslothian.scot.nhs.uk/YourRights/EqualityDiversity/Pages/ImpactAssessment.aspx and available for auditing purposes. Copies of previous impact assessments are available on the NHS Lothian website under Equality and Diversity.